Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
22 mars 2023 16h40 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463)...
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
22 nov. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
06 oct. 2022 08h00 HE
|
Cyclerion Therapeutics, Inc.
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
09 août 2022 16h00 HE
|
Cyclerion Therapeutics, Inc.
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
28 juil. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well...
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
26 juil. 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
28 juin 2022 09h00 HE
|
Cyclerion Therapeutics, Inc.
Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients Company leadership discussed key insights for...
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
22 juin 2022 08h30 HE
|
Cyclerion Therapeutics, Inc.
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on...
Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease
17 juin 2022 08h00 HE
|
Cyclerion Therapeutics, Inc.
CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS...
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
10 juin 2022 07h00 HE
|
Cyclerion Therapeutics, Inc.
Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463...